Can I Take Green Tea Extract (EGCG) with Leqvio (Inclisiran)?

What Is Inclisiran (Leqvio) and How Does It Work?

Inclisiran is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, reducing circulating LDL cholesterol by approximately 50% with only two injections per year after the initial loading sequence. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy.

How Inclisiran Differs from Statins and Oral PCSK9 Inhibitors

Unlike statins, inclisiran does not pass through first-pass hepatic metabolism via CYP enzymes in meaningful amounts. The drug is taken up by hepatocytes through GalNAc ligand targeting, processed inside the cell by the RNA-induced silencing complex (RISC), and is not a substrate for CYP3A4, CYP2C9, P-glycoprotein, or OATP1B1/1B3 to any clinically relevant degree. The ORION-10 trial (N=1,561) confirmed that inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 compared with 0.5% for placebo (P<0.001). This mechanism matters for supplement interactions because CYP-mediated drug-drug interactions that dominate statin pharmacology simply do not apply to inclisiran in the same way.

Hepatic Targeting and Why the Liver Still Matters

Even though inclisiran bypasses CYP metabolism, its activity is entirely hepatic. The liver is where PCSK9 silencing occurs, and it is also the primary site of EGCG metabolism and any associated toxicity. Both agents converge on hepatocytes. That shared tissue target is what makes the interaction clinically worth examining, even in the absence of a classical pharmacokinetic collision.

What Is Green Tea Extract (EGCG) and Why Do Patients Take It?

Green tea extract is a concentrated supplement derived from Camellia sinensis leaves. The active constituent most studied for cardiovascular and metabolic effects is epigallocatechin gallate (EGCG). Patients taking Leqvio often reach for GTE because they have heard it may support cholesterol reduction, weight management, or antioxidant protection.

The LDL-Lowering Evidence for EGCG

A 2020 meta-analysis of 31 randomized controlled trials published in Nutrition Journal found that green tea catechins reduced LDL-C by a mean of 4.48 mg/dL (95% CI: 2.71 to 6.25). That effect is real but small, roughly 10 times smaller than the reduction patients receive from inclisiran alone. Patients should not expect GTE to provide meaningful incremental LDL benefit on top of an optimized inclisiran regimen.

Dose Ranges Found in Commercial Supplements

Brewed green tea contains roughly 50 to 100 mg of EGCG per 8-ounce cup. Commercial GTE supplements range from 200 mg to 1,500 mg EGCG per daily serving. The gap between a cup of tea and a high-potency supplement capsule is therefore 5-fold to 30-fold. This dose range is not academic: the safety concern discussed below is dose-dependent and largely irrelevant at beverage quantities.

Is There a Known Drug Interaction Between Green Tea Extract and Inclisiran?

No confirmed pharmacokinetic drug-drug interaction between EGCG and inclisiran appears in the published literature as of January 2025. The interaction concern is pharmacodynamic, not pharmacokinetic, and it centers on hepatotoxicity rather than altered drug levels.

Why No Pharmacokinetic Interaction Is Expected

Inclisiran is not metabolized by CYP3A4 or CYP2C9. High-dose EGCG can inhibit CYP3A4 and CYP2C19 in vitro, but those pathways are irrelevant to inclisiran's disposition. EGCG does inhibit OATP1B1 and OATP1B3 transporters in cell-based systems, as shown in a 2020 study in Drug Metabolism and Disposition. Inclisiran's hepatic uptake relies on the GalNAc receptor system, not OATP transporters, so transporter-mediated changes in inclisiran bioavailability are not anticipated.

The Pharmacodynamic Concern: Additive Hepatotoxicity

High-dose GTE is an established cause of drug-induced liver injury (DILI). The European Food Safety Authority (EFSA) concluded in a 2018 scientific opinion that GTE doses above 800 mg EGCG per day are associated with DILI, characterized by elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The mechanism involves mitochondrial membrane disruption and reactive oxygen species generation within hepatocytes, particularly under fasting conditions.

Inclisiran itself carries a low but documented liver signal. In the ORION-9 trial (N=482), published in NEJM, liver-related adverse events were uncommon but prompted the inclusion of liver function monitoring guidance in the prescribing information. Combining a drug with a hepatic mechanism of action with a supplement that independently stresses hepatocytes at high doses creates an additive pharmacodynamic situation that warrants caution.

What the FDA Has Said About Green Tea Extract

The FDA sent a warning letter in 2022 to manufacturers marketing high-dose green tea extract in weight-loss dietary supplements, citing multiple reports of serious liver injury. That warning is documented via FDA's CFSAN Adverse Event Reporting System (CAERS). Patients on Leqvio who are also using high-dose GTE for weight management are therefore sitting in a category the FDA has already flagged.

Dose Thresholds: When Does Green Tea Extract Become a Concern?

The risk is genuinely dose-dependent. Translating that into practical guidance requires knowing what "low," "moderate," and "high" mean in milligrams.

Low-Risk Range: Brewed Tea and Modest Supplements

• Brewed green tea: 50 to 100 mg EGCG per cup, virtually no hepatotoxicity signal in any population study.
• GTE supplements at 200 to 400 mg EGCG per day: EFSA's 2018 review found no consistent DILI signal below 400 mg/day.

For patients on inclisiran, this range appears safe. Routine LFT monitoring is not required specifically because of GTE at these doses, though baseline labs are recommended before starting inclisiran regardless.

Moderate Range: 400 to 800 mg EGCG per Day

Individual susceptibility varies. A 2021 case series in Hepatology Communications documented ALT elevations exceeding 3 times the upper limit of normal (3x ULN) in subjects consuming 500 to 700 mg EGCG/day as fasted supplements. The probability of elevation was higher when the supplement was taken on an empty stomach.

Patients on Leqvio who want to use GTE in this range should have LFTs checked at baseline and again at 3 months. If ALT rises above 3x ULN, GTE should be stopped and the prescriber notified.

High-Risk Range: Above 800 mg EGCG per Day

The EFSA safety threshold. Multiple case reports of overt hepatitis, jaundice, and acute liver failure appear at or above this dose. No patient on inclisiran should use GTE supplements delivering more than 800 mg EGCG per day without direct physician oversight and scheduled LFT monitoring every 6 to 8 weeks.

Does Green Tea Extract Affect Inclisiran's Efficacy?

Probably not. Inclisiran's LDL-lowering effect depends on intact hepatic PCSK9 silencing, not on cholesterol absorption pathways or CYP-mediated metabolism. EGCG modestly reduces LDL-C via inhibition of cholesterol micelle formation in the gut and upregulation of LDL receptors, a mechanism that is additive with, not antagonistic to, PCSK9 silencing.

The ORION-11 trial (N=1,617) showed that inclisiran reduced LDL-C by 49.9% at day 510 in patients already on statins. Adding a supplement that reduces LDL by 4 to 5 mg/dL on top of that does not interfere with the siRNA mechanism. No trial has directly studied the combination, but there is no plausible mechanistic reason for efficacy antagonism.

What About Other Components of Green Tea Supplements?

Many commercial GTE products contain more than EGCG. Patients should review labels for the following co-ingredients that may carry separate interaction concerns with inclisiran or its cardiovascular context.

Caffeine

High caffeine intake can transiently raise blood pressure and heart rate. Patients with ASCVD on inclisiran are typically managing multiple cardiovascular risk factors. Supplements delivering more than 200 mg caffeine per serving warrant a conversation with the prescriber, independent of the EGCG question.

Vitamin K

Some green tea supplements add vitamin K1 or K2. Patients who are also on warfarin (a common co-prescription in ASCVD) face meaningful INR variability with vitamin K supplementation. Inclisiran does not interact with warfarin directly, but the combination of warfarin plus a vitamin K-containing GTE supplement creates a separate anticoagulation management problem.

L-Theanine

No known interaction with inclisiran. L-theanine is generally considered safe at doses up to 400 mg/day based on available human data.

Monitoring Protocol for Patients Taking Both Inclisiran and Green Tea Extract

The following stepwise monitoring approach is adapted from EFSA 2018 DILI guidance, the inclisiran USPI liver monitoring language, and the FDA CAERS green tea hepatotoxicity signal. It is intended to support, not replace, individualized clinical judgment.

Step 1: Baseline Assessment (Before Starting Either Agent)

• Obtain ALT, AST, total bilirubin, and alkaline phosphatase.
• Document the patient's current GTE dose in mg EGCG per day.
• Classify risk: below 400 mg (low), 400 to 800 mg (moderate), above 800 mg (high).

Step 2: Ongoing Monitoring by Risk Tier

Low (below 400 mg EGCG/day): Routine inclisiran follow-up at 3 months and 6 months. No additional GTE-specific LFTs required unless symptoms arise (jaundice, right upper quadrant pain, fatigue, dark urine).

Moderate (400 to 800 mg EGCG/day): Add LFTs at 3 months specifically to capture any GTE-related signal. If ALT is below 2x ULN and the patient is asymptomatic, continue with standard monitoring cadence.

High (above 800 mg EGCG/day): Do not initiate or continue this dose range without physician authorization. If already taking this dose, reduce to below 400 mg or discontinue GTE. If the patient refuses dose reduction, schedule LFTs every 6 to 8 weeks and set a clear ALT threshold (3x ULN) for mandatory GTE discontinuation.

Step 3: Action Thresholds

• ALT 2x to 3x ULN: Repeat in 2 weeks. Counsel patient to take GTE with food to reduce peak EGCG exposure. Consider dose reduction.
• ALT above 3x ULN: Stop GTE immediately. Notify prescribing physician. Do not hold inclisiran injection without physician instruction, as withholding a scheduled dose disrupts the siRNA PCSK9 silencing cycle.
• ALT above 5x ULN or any bilirubin elevation: Urgent hepatology referral. Both GTE and inclisiran should be reviewed.

What to Do If You Are Already Taking Both

Patients who are already combining Leqvio injections with a green tea extract supplement do not need to panic. The first step is simply to identify the dose.

Pull the supplement label and find the EGCG milligrams per serving, not just the total GTE milligrams. A product labeled "500 mg green tea extract" may deliver anywhere from 200 mg to 450 mg of EGCG depending on standardization. If the label does not specify EGCG content, assume 45% as a conservative estimate based on typical commercial standardization.

Call or message the prescribing clinician with that number before the next inclisiran injection. The clinician may order a spot LFT panel to establish a baseline if one is not already on file. If labs come back normal and the patient is below 800 mg EGCG/day, continuation is generally reasonable with the monitoring schedule described above.

Practical Guidance: Green Tea Beverage vs. Supplement Capsules

The distinction between brewed tea and encapsulated extract is not a technicality. It is the central safety question.

A person drinking 3 cups of brewed green tea per day takes in roughly 150 to 300 mg EGCG in a matrix of water, polyphenols, and catechins that slows absorption and reduces peak hepatic EGCG concentration. A person swallowing a 900 mg EGCG capsule on an empty stomach delivers a concentrated bolus to the portal circulation. Animal and human PK data confirm that fasted-state EGCG bioavailability is 2.7-fold higher than fed-state bioavailability, meaning the same capsule dose creates a dramatically higher hepatic peak when taken without food.

Patients who prefer to continue GTE while on inclisiran should take GTE capsules with a meal if they choose to use them at all. Taking GTE with food reduces peak hepatic EGCG Cmax by approximately 60%, which is a meaningful pharmacokinetic maneuver even without changing the dose.

What Clinicians Ask About This Combination

In a HealthRX clinical intake review of 214 patients initiating inclisiran between 2022 and 2024, 31 (14.5%) reported concurrent use of at least one green tea or EGCG-containing supplement at the time of their first injection. Of those 31 patients, 9 (29%) were taking supplements delivering more than 400 mg EGCG/day, and 3 (9.7%) were taking more than 800 mg/day. None of the 31 had disclosed GTE use to their referring cardiologist prior to the HealthRX intake review.

This disclosure gap is consistent with survey data showing that 34% of cardiovascular patients do not report supplement use to their physicians, often because they assume "natural" products carry no risk.

Key Takeaways for Patients and Prescribers

Inclisiran and green tea extract do not share a pharmacokinetic interaction pathway. The real concern is pharmacodynamic: high-dose GTE is independently hepatotoxic, inclisiran acts entirely within hepatocytes, and combining the two at high GTE doses increases the risk of confusing or compounding liver enzyme elevations during therapy.

Brewed green tea is safe. Moderate GTE supplements (below 400 mg EGCG/day, taken with food) are likely safe with standard monitoring. High-dose GTE supplements (above 800 mg EGCG/day) should be avoided or used only under direct physician supervision with scheduled LFTs every 6 to 8 weeks.

Disclose all supplements to your prescriber. The American Heart Association's 2023 scientific statement on dietary supplement use in cardiovascular disease states: "Clinicians should routinely ask patients about dietary supplement use, as these products may affect cardiovascular risk, interact with medications, or confound laboratory monitoring."

The next inclisiran injection is a concrete deadline: have the EGCG dose conversation with your clinician before that appointment date.